Clinical Trials Logo

Stage IV Melanoma clinical trials

View clinical trials related to Stage IV Melanoma.

Filter by:

NCT ID: NCT00085189 Completed - Stage IV Melanoma Clinical Trials

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Start date: May 2004
Phase: Phase 2
Study type: Interventional

This pilot phase II trial studies how well giving vaccine therapy works in treating patients with stage IIC-IV melanoma. Vaccines made from melanoma peptides or antigens may help the body build an effective immune response to kill tumor cells

NCT ID: NCT00082875 Terminated - Stage IV Melanoma Clinical Trials

Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma

Start date: March 2004
Phase: Phase 2
Study type: Interventional

This randomized phase II trial is studying how well cilengitide works in treating patients with unresectable stage III or stage IV melanoma. Cilengitide may stop the growth of melanoma by stopping blood flow to the tumor.

NCT ID: NCT00074308 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers

Start date: October 2003
Phase: Phase 1/Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of combining imatinib mesylate with bevacizumab in treating patients who have advanced melanoma or other metastatic or unresectable cancer. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Bevacizumab may stop the growth of tumor cells by stopping blood flow to the tumor. Combining imatinib mesylate with bevacizumab may kill more tumor cells

NCT ID: NCT00072189 Terminated - Stage IV Melanoma Clinical Trials

A Phase II Study of UCN-01 in Metastatic Melanoma

Start date: November 2003
Phase: Phase 2
Study type: Interventional

UCN-01 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. This phase II trial is studying how well UCN-01 works in treating patients with metastatic melanoma.

NCT ID: NCT00072163 Completed - Stage IV Melanoma Clinical Trials

Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma

Start date: October 2003
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well giving temozolomide together with thalidomide works in treating patients with brain metastases secondary to melanoma. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining temozolomide with thalidomide may kill more tumor cells

NCT ID: NCT00060125 Completed - Stage IV Melanoma Clinical Trials

Tipifarnib in Treating Patients With Metastatic Malignant Melanoma

Start date: May 2003
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well tipifarnib works in treating patients with metastatic malignant melanoma. Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.

NCT ID: NCT00039091 Terminated - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer

Start date: March 2002
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects of monoclonal antibody therapy in treating patients with ovarian epithelial cancer, melanoma, acute myeloid leukemia, myelodysplastic syndrome, or non-small cell lung cancer. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells

NCT ID: NCT00036764 Completed - Stage IV Melanoma Clinical Trials

BMS-247550 in Treating Patients With Stage IV Melanoma

Start date: February 2002
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of BMS-247550 in treating patients who have stage IV melanoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

NCT ID: NCT00030615 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Decitabine in Treating Patients With Advanced Solid Tumors

Start date: December 2001
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of decitabine in treating patients with advanced solid tumors that have not responded to previous treatment. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

NCT ID: NCT00026143 Completed - Stage IV Melanoma Clinical Trials

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

Start date: October 2001
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of combining interleukin-12 and interferon alfa in treating patients who have metastatic malignant melanoma. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Interferon alfa may interfere with the growth of the cancer cells. Combining interleukin-12 and interferon alfa may kill more tumor cells.